Why Peptide Prices Vary Tenfold

ON THIS PAGE

1. Key findings
2. What a price actually has to cover
3. What the cheap end of this ledger looks like on paper
4. What the expensive end looks like on paper
5. When a low price is information
6. Limitations and open questions
7. Sources

A 10mg vial of retatrutide costs $8.90 at one seller in this ledger and $200.00 at another. Both prices are for the same compound at the same size, recorded between August 17 and August 26, 2026, across 53 price records, from 50 suppliers, that state a comparable US dollar figure. Neither number tells a buyer what is inside the vial. Together, they tell a buyer that price alone answers nothing, and that the gap between them has to come from somewhere.

What a price actually has to cover

A vial that reaches a buyer's door has passed through steps that cost money whether or not a seller discloses them. Synthesis at a meaningful scale and purification depth, the chromatography passes that separate a target peptide from the truncated and deletion sequences solid-phase synthesis produces as a matter of course, cost more the closer a batch gets to a high purity figure. Testing costs money per batch: an outside laboratory does not run an HPLC purity assay, a mass-spectrometry identity check, and an endotoxin screen for free, and a seller that pays for all three on every lot is paying for something a seller that pays for none is not. Running a business inside the rules costs money too, in ways that show up nowhere on a product page: a registered legal entity, staff who answer a support ticket, and a card processor willing to underwrite chargebacks all add cost that a storefront skipping them does not carry. None of this proves what any specific seller actually spent. It says only that a price at the low end of a twenty-two-fold range has less room in it to have paid for these things than a price at the high end does, and a buyer can check which of them the seller shows evidence of separately from checking the price itself.

What the cheap end of this ledger looks like on paper

Three of the six lowest-priced records in this range carry a documentation gap on the exact thing being sold. Qingdao Sigma Chemical, at $9.50 per vial read 2026-08-20, displays a four-badge verification panel on its product page in which only one of the four names an independently recognized laboratory, Janoshik Analytical; the other three withhold the identity of whoever tested the batch, and no purity figure, lot number, or test date appears as text on the report pages themselves. SCYRX, at $32.00 read 2026-08-26, states purity figures as marketing copy on its product pages with no named laboratory behind any of them, and the actual certificate is gated behind an email request the vendor says takes up to a business day; the standard commerce pages a buyer would expect, contact, shipping, terms, and privacy, each return a 404, and the footer links on every page labelled Contact, Shipping, Terms, and Privacy point at a dead anchor rather than at a real address. GreyLabs, at $19.39 per vial read 2026-08-25, is a sharper case still: the only retatrutide certificate on file anywhere covers a 20mg batch, while the 10mg kit, the size actually priced here, is sold with no published document at all.

Not every cheap record reads that way, and the one that does not is the reason this piece is about documentation rather than price. S1 Research (Step One Ventures), at $30.00 read 2026-08-24, sits between GreyLabs and SCYRX on this list and publishes a certificate per product and per size on its own domain. The 10mg document names Freedom Diagnostics as the issuing laboratory and carries a lot number, an accession number, a purity figure by HPLC with UV detection, an identity line by LC-MS, and an endotoxin result by the Limulus Amebocyte Lysate method. The laboratory's own public register returns that same file, and the copy the laboratory hosts matches the image the vendor publishes field for field. So the cheap end of this range does not sort neatly. The gaps above are findings about three specific records, not a property of a low price.

What the expensive end looks like on paper

Grey Research Peptides, at $200.00 read 2026-08-25, is the single most expensive record in this range, and it is also one of the more heavily documented: 32 certificates pulled directly from its named testing laboratory's own domain, covering the purity and identity assays its quality and testing page lists as standard. That documentation still carries a real gap. None of the 32 certificates carries an endotoxin line, while that same quality and testing page puts endotoxin testing, by the Limulus Amebocyte Lysate method against a stated acceptance ceiling, in the list of tests it calls standard. The site's own FAQ says the reverse, that endotoxin testing is something a buyer has to request separately beyond the standard certificate, so the vendor's pages state two different things about the same test. A higher price and a larger certificate library do not mean a clean record. They mean there is more to check, and more that can be checked, than a seller with no certificate offers at all. One thing neither end of this range establishes is laboratory accreditation: neither laboratory named in this piece claims one on its own site, and the words accreditation, ISO 17025, A2LA and CLIA appear on neither.

When a low price is information

A low price is not, by itself, evidence of anything wrong. Synthesis costs fall as scale grows, and a seller running efficiently can legitimately charge less than one running inefficiently. What turns a low price into information is what sits beside it. This publication's own evaluation method starts with the certificate precisely because it is the fastest thing to check, and a price that comes with no certificate, one gated behind a request, or one for the wrong batch size is a documentation finding independent of whether the price itself turns out to be fair. The stages this publication has documented in vendors that later go quiet start somewhere else entirely, with card payment vanishing from checkout, then certificate dates that stop advancing, then support that slows; that piece describes suppliers that had decent documentation and working support before any of it began. Its pattern is a change over time in a vendor that is still operating. A documentation gap read on one day is a finding about that day, and neither reading is evidence for the other.

Limitations and open questions

This piece compares one benchmark, a single 10mg retatrutide vial, priced in US dollars, across 53 price records held by 50 of the 126 supplier records in this ledger, two of those suppliers carrying more than one qualifying package size; a different compound or a different size could show a different spread, and this piece makes no claim about pricing for anything else. The prices themselves were read on the dates given, between 2026-08-17 and 2026-08-26, and a storefront's price can change at any time afterward. Kit prices were divided by vial count to reach a per-vial figure, which assumes each vial in a kit is priced evenly; records for a size other than 10mg were excluded rather than estimated, and every price in this ledger is recorded in US dollars, so nothing had to be converted. Nothing here establishes that any specific vendor's product does or does not match its price, its certificate, or its own marketing claims beyond what is stated above with a source. A low price and thin documentation appearing together is a pattern worth noticing, not a verdict on the seller carrying it.

The price on a product page is the easiest number on it to read and the least useful one to trust alone. The certificate behind it, or the absence of one, is where the twenty-two-fold gap actually lives.

Sources

Supplier observations and prices are this publication's own, from the dossier record in ledger/vendors.json: Qingdao Sigma Chemical and Grey Research Peptides, both read 2026-08-20 and 2026-08-25 respectively for documentation, with Qingdao Sigma's price read 2026-08-20 and Grey Research Peptides' price read 2026-08-25; GreyLabs, documentation and price read 2026-08-25; SCYRX, documentation and price read 2026-08-26; and S1 Research (Step One Ventures), documentation and price read 2026-08-24. The price range and the $89.95 median were computed across all 53 comparable US dollar records directly from ledger/vendors.json on 2026-09-18. Vendors are named here, never linked, per site policy.